Chemin des Aulx, 12
94 articles with ObsEva
ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland
ObsEva SA announced that Ernest Loumaye, MD, PhD, co-founder and member of the Board of Directors has been appointed as Interim Chairman following the resignation of Annette Clancy.
ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland
ObsEva SA announced a strategic reorganization that will consolidate operations in Switzerland so as to preserve cash, focus resources towards the development of nolasiban, a novel, oral oxytocin receptor agonist to improve in vitro fertilization success rates, and manage its out-licensed programs.
ObsEva Announces Dismissal of Moratorium Proceedings
ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies for women’s health, announced that the competent court in Geneva, Switzerland has granted the Company’s request to withdraw its moratorium considering that the Company is no longer over-indebted.
ObsEva To Increase Issued Share Capital by Creating Additional Treasury Shares
ObsEva SA announced that its board of directors approved on December 8, 2022 an increase of its share capital through the issuance of 20,000,000 newly registered shares at an issue price of 1/13 of a Swiss Franc each.
XOMA Acquires Royalty and Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by Organon
XOMA assumes the rights to ebopiprant from ObsEva, including the Organon License, Patent Estate, and Merck KGaA, Darmstadt, Germany, license, for a $15 million outlay.
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium Proceedings
ObsEva SA announced that the transition of the linzagolix program to Kissei Pharmaceutical Co., Ltd. is substantially complete following the assignment of substantially all clinical, manufacturing, and scientific contracts related to the development of linzagolix.
ObsEva Announces Progress on Restructuring Initiatives
ObsEva SA, a biopharmaceutical company developing novel therapies for women’s health, announced an update on its previously announced restructuring efforts.
The FDA is heading into fall with a few Prescription Drug User Fee Act (PDUFA) dates. Here's a look at this week's upcoming action.
ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing
GENEVA, Switzerland – August 1, 2022 – ObsEva SA, a biopharmaceutical company developing novel therapies for women’s health, announced the early retirement of $31 million in debt that was part of amounts owed to certain funds and accounts managed by JGB Management, Inc. pursuant to the Company’s Securities Purchase Agreement with JGB.
On Wednesday, Swiss women’s health company ObsEva announced that it is dropping linzagolix, its leading candidate for uterine fibroids.
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
ObsEva SA (NASDAQ: OBSV; SIX: OBSN), today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization for Yselty® (linzagolix), an oral GnRH antagonist, for the management of moderate to severe symptoms of uterine fibroids (UF) in adult women (over 18 years of age) of reproductive age.
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy.
ObsEva Announces Corporate Updates - May 27, 2022
ObsEva SA announced that it has entered into a waiver and amendment agreement with respect to its amended and restated securities purchase agreement with certain funds and accounts managed by JGB Management, Inc., which is structured to provide up to $135 million in borrowing capacity, available in nine tranches.
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses
ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the presentation of clinical data on linzagolix, an oral GnRH antagonist.
ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2022 Annual General Meeting held on May 18, 2022
ObsEva SA announced that shareholders approved all Board proposals at its 2022 Annual General Meeting held on May 18, 2022.
ObsEva Announces Appointment of Annette Clancy as Chair of the Board of Directors
ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the appointment of Annette Clancy as Chair of the Board of Directors at the Company’s Annual General Meeting on May 18, 2022.
ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update
ObsEva SA reported financial results for the first quarter ended March 31, 2022 and provided a business update.
ObsEva to Present at the H.C. Wainwright Global Investment 2022 Conference
ObsEva SA announced that Company Management will provide a corporate update at the upcoming H.C. Wainwright Global Investment Conference, taking place virtually and in Miami, Florida from May 23 – 26, 2022.
ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer
ObsEva SA announced the appointment of Dr. Brandi Howard as Chief Clinical Officer and member of the company’s Executive Committee, effective May 9, 2022.
ObsEva Annual General Meeting 2022
ObsEva SA published the invitation to its 2022 Annual General Meeting of Shareholders to be held on May 18, 2022 at 16:30 CEST at the company's offices in Geneva, Chemin des Aulx 12, 3rd floor, 1228 Plan-les-Ouates, Switzerland.